Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047263 · ClinicalTrials.gov registry record · Phase 3
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,584
- Enrollment target
NCT05047263: Completed Phase 3 study, sponsored by Bayer.
NCT05047263 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 1,584 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05047263, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,584 participants
- Enrollment target
Study Summary
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certain hormone called aldosterone that causes injury and inflammation in the heart and kidney which is known to play a role in CKD. In this trial, the researchers want to learn if finerenone helps to slow down the worsening of the participants' non-diabetic CKD compared to a placebo. A placebo looks like a trial treatment but does not have any medicine in it. The trial will include about 1,580 men and women who are at least 18 years old. The participants will take finerenone or a placebo once a day as tablets by mouth. All of the participants will also continue to take their current medicine for their CKD. The participants will be in the trial for up to about 50 months. During the trial, the doctors will collect blood and urine samples and check the participants' health. The participants will also answer questions about how they are feeling and what adverse events they are having. An adverse event is a medical problem that happens during the trial. Doctors keep track of all adverse events that happen in trials, even if they do not think the adverse events might be related to the trial treatments.
Primary Outcome
eGFR: Estimated glomerular filtration rate
Interventions
- DRUG Placebo
- DRUG Finerenone (BAY94-8862)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,584 participants |
| Start Date | 2021-09-21 |
| Est. Completion | 2026-02-02 |
| Phase | Phase 3 |
What the finished NCT05047263 record still lists
NCT05047263 is an interventional study that assigns participants to a tested intervention. Its 1,584 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (105% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05047263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05047263 about?
NCT05047263 is a clinical study titled "A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease". Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finerenone, is being developed to help people who have long lasting kidney disease, also known as chronic kidney disease (CKD). It works by blocking a certai...
What is the current status of trial NCT05047263?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,584 participants. The study started on 2021-09-21. Estimated completion is 2026-02-02.
What interventions are being tested in trial NCT05047263?
The interventions under investigation include: Placebo (DRUG), Finerenone (BAY94-8862) (DRUG).
Who is sponsoring clinical trial NCT05047263?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05047263's enrollment target sits among peer trials
1,584 149th of 2000 higher than 1,852 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05483855 · 1,580 participants
Telehealth-delivered HealthcaRe to ImproVe Care
- NCT05552222 · 1,590 participants · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- NCT06632457 · 1,590 participants · Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- NCT05243797 · 1,594 participants · Phase 3
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI